Idiopathic Pulmonary Fibrosis (IPF) is a progressive, chronic, and often fatal interstitial lung disease. Its complex pathophysiology continues to pose major challenges in drug development. To address this unmet need, Prisys Biotech is expanding its nonhuman primate (NHP) disease model platform and launch a novel cynomolgus monkey IPF model. This new model is designed to provide more accurate, clinically translatable insights for IPF drug discovery and development.
Model Overview
The Prisys Biotech IPF model aims to replicate the pathological hallmarks of human chronic progressive fibrosing interstitial pneumonia. By reconstituting the disease phenotype in cynomolgus monkeys, this model offers a reliable platform to:
- Investigate mechanisms of IPF onset and progression
- Identify and validate novel therapeutic targets
- Evaluate efficacy and safety of candidate therapeutics
Core Evaluation Endpoints
CT-based fibrosis assessment: High-resolution CT imaging provides quantitative evaluation of pulmonary fibrosis.
Lung volume calculation & CTA: Advanced imaging capabilities enable precise assessment of lung function and pulmonary artery changes.
Prisys Biotech's Supporting Capabilities
1. Comprehensive Respiratory Research Platform
Equipped with a dedicated pulmonary laboratory and aerosol biology lab, Prisys Biotech provides integrated capabilities for respiratory disease research. Facilities include:
- Large-animal temperature-controlled surgical beds
- Lung function measurement systems
- Bronchoscopy for airway evaluation
- Advanced biosafety systems for controlled experimentation
2. Advanced Drug Delivery Methods
Specialized in multiple administration routes-including inhalation, intratracheal, bronchial, and catheter-based delivery-Prisys ensures efficient targeting to the lungs. Core devices such as the Aerogen nebulization system enhance localized delivery and reproducibility.
3. Clinical Imaging
Prisys Biotech's imaging team, comprised of radiologists with over 50 years of combined clinical experience, operates a full suite of clinical-grade systems:
- 1.5T MRI
- 40-slice CT
- Doppler ultrasound
- Endoscopic imaging
These tools provide comprehensive pulmonary imaging for diagnosis, disease progression monitoring, and treatment evaluation.
4. Pulmonary Function Testing
Integrated into safety pharmacology and toxicology assessments, lung function testing delivers objective data on drug effects on respiratory physiology.
5. Experienced Scientific Team
The Prisys Biotech team averages 15+ years of NHP research experience, ensuring high-quality study design, execution, and data interpretation.
Looking Ahead
With a portfolio of 40+ established cynomolgus monkey disease models, including multiple respiratory indications, Prisys Biotech continues to set the benchmark for translational large-animal research. The upcoming IPF NHP model reinforces our leadership in respiratory disease modeling and provides a vital bridge between preclinical discovery and clinical translation.
By collaborating with global pharmaceutical and biotech partners, Prisys Biotech is committed to advancing IPF research and accelerating the development of innovative therapies that bring hope to millions of patients worldwide.
Contact Us
For more information on Prisys Biotech's IPF model and respiratory disease research platform:
Email: bd@prisysbiotech.com
